EMA Authorised: Olumiant (Baricitinib) — Eli Lilly Nederland B.V.

View source ↗

Summary

EU authorities authorised Olumiant (baricitinib) for rheumatoid arthritis with decision date 30 March 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Olumiant (baricitinib)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid. MAH: Eli Lilly Nederland B.V.. Decision date: 30/03/2026